A Lung Cancer Vaccine: How it Works & Current Status

Lung cancer vaccines are therapeutic vaccines designed to teach the immune system to recognize and attack tumor cells that it would otherwise ignore. Unlike the vaccines most people are familiar with, these are not given to healthy people to prevent cancer from forming in the first place. Instead, they are administered to patients who already have lung cancer, with the goal of shrinking tumors or keeping the disease from progressing. Several approaches are now in clinical trials, from mRNA-based shots developed by BioNTech to a protein-based vaccine that has been used in Cuba for years, and the science behind them draws on the same immunological toolkit that made COVID-19 vaccines possible.

How a Lung Cancer Vaccine Differs from a Flu Shot

When you get a flu vaccine, your immune system learns to recognize a virus before you encounter it. A lung cancer vaccine works in a fundamentally different direction. Cancer cells arise from your own tissue, so the immune system tends to treat them as “self” rather than as invaders. Tumors also actively suppress immune responses in their surrounding environment, making it even harder for immune cells to mount an attack. A therapeutic cancer vaccine essentially gives the immune system a cheat sheet: here is what the cancer cells look like, and here is why they deserve to be destroyed.

The cheat sheet usually consists of proteins or genetic instructions for proteins that are found on tumor cells but not on healthy tissue. Once the immune system sees these targets in the context of a vaccine, it can generate specialized T cells that seek out and kill cells displaying those same targets. The challenge, and the reason lung cancer vaccines have taken decades to develop, is finding the right targets and delivering them in a way that produces a strong enough immune response to matter.

What the Immune System Needs to See

The targets that matter most for lung cancer vaccines are called neoantigens. These are proteins that arise specifically from mutations in tumor DNA. Because they exist only in cancer tissue and not in healthy cells, the immune system can attack them without causing collateral damage. This makes neoantigens ideal vaccine targets with high specificity and low risk of triggering autoimmune problems.¹

Lung cancer turns out to be a particularly promising setting for neoantigen-based vaccines. Non-small cell lung cancer, which accounts for roughly 85% of all lung cancers, tends to carry a high tumor mutation burden. More mutations mean more potential neoantigens for the immune system to latch onto. This advantage is especially pronounced in patients with a history of smoking, whose tumors accumulate far more DNA damage than those in never-smokers.²

Not every mutation produces a useful neoantigen, though. Finding the right ones requires sequencing both the tumor and the patient’s normal tissue, then using computational tools to predict which mutated proteins will bind well to the patient’s immune molecules and actually provoke a T-cell response. Prediction tools evaluate how strongly a mutated peptide will interact with a patient’s specific immune receptors, and newer pipelines are using deep learning to speed up and improve this process.³ In one case study of a patient with relatively few tumor mutations, researchers screened 18 mutated genes and found that five produced immune-reactive targets, with one neoantigen arising from a frameshift deletion in the KEAP1 gene driving a particularly focused T-cell response.⁴

The Main Vaccine Platforms

There is no single “lung cancer vaccine.” Several fundamentally different technologies are being tested, each with its own trade-offs in terms of speed, cost, and how well it activates the immune system.

mRNA Vaccines

The same lipid-nanoparticle technology behind the Pfizer-BioNTech COVID vaccine is now being repurposed for cancer. An mRNA lung cancer vaccine delivers genetic instructions that tell the patient’s own cells to produce tumor-associated proteins, which the immune system then learns to recognize. BioNTech’s BNT116, for example, is a fixed-antigen mRNA vaccine encoding multiple lung-cancer-associated targets. It can be manufactured in a standardized, cell-free process, which makes production faster and more scalable than patient-specific approaches.⁵ The personalized alternative, exemplified by BioNTech’s BNT122 platform, sequences an individual patient’s tumor and builds a custom mRNA vaccine encoding that person’s unique neoantigens.

Protein-Based Vaccines

CIMAvax-EGF, developed in Cuba, takes a completely different approach. Rather than targeting the tumor directly, it targets epidermal growth factor (EGF), a normal protein that many lung cancers depend on for growth. The vaccine is a chemical conjugate of human EGF with a bacterial carrier protein, plus an adjuvant to boost the immune response.⁶ When the vaccine works, the patient produces antibodies that mop up circulating EGF, effectively starving the tumor of a key growth signal.⁷ CIMAvax-EGF has been approved for use in Cuba and several other countries, making it the most clinically mature lung cancer vaccine in the world.

Dendritic Cell Vaccines

Dendritic cells are the immune system’s alarm-raisers. They pick up foreign material, process it, and present it to T cells, which then mount a targeted attack. Dendritic cell vaccines exploit this by removing a patient’s own immune precursor cells, growing them in the lab, loading them with tumor-specific proteins, and then injecting them back into the patient.⁸ The loaded dendritic cells act as teachers, instructing the patient’s T cells on what the cancer looks like. The drawback is that this process is labor-intensive and patient-specific, and the effectiveness of the re-injected cells can be blunted by the tumor’s immunosuppressive environment.⁹

Inhaled Vaccines and Lipid Nanoparticle Delivery

One of the more intriguing newer ideas is delivering cancer vaccines directly to the lungs via inhalation. In mouse studies, a specially designed lipid nanoparticle called CAS-LNP was used to deliver mRNA encoding a tumor antigen straight into the airways. The inhaled vaccine boosted the proportion of tumor-killing T cells by roughly 21-fold compared to a saline control and significantly reduced the number of metastatic tumors in the lungs. It also shifted the balance of immune cells in the lungs toward a more inflammatory, anti-tumor state.¹⁰

A separate approach used mannose-modified lipid nanoparticles to deliver both a gene-silencing molecule and an immune-activating mRNA directly to tumor-supporting immune cells in the lungs. When combined with checkpoint inhibitor drugs, this treatment significantly enhanced anti-tumor immune responses in mouse models of both primary lung cancer and lung metastases.¹¹ These are still preclinical results, but the logic is appealing: delivering the vaccine where the cancer lives could concentrate the immune response right where it is needed most.

Where Clinical Trials Stand

The clinical picture for lung cancer vaccines is a mix of cautious optimism and sobering history. Several earlier vaccine candidates made it to large phase III trials but ultimately failed to improve survival. The MAGE-A3 vaccine was tested in resected early-stage disease, L-BLP25 was studied in locally advanced disease after chemoradiation, and others like belagenpumatucel-L and TG4010 were tested alongside chemotherapy in advanced-stage patients.¹² None of these produced the survival gains needed for approval in major markets.

The newer generation of vaccines, particularly the mRNA-based candidates, is where the energy has shifted. BioNTech’s BNT116 has produced early clinical data from the LuCa-MERIT-1 trial. Among 18 patients with advanced non-small cell lung cancer who had failed multiple prior treatment lines, the vaccine was generally well tolerated. The most common side effects were fever and chills. Among ten patients evaluable for tumor response, six had stable disease. No dose-limiting toxicities or treatment-related deaths occurred.¹³ These are very early-phase results in heavily pretreated patients, so the bar here is showing safety and a signal of immune activity, not dramatic tumor shrinkage. Ongoing trials are now testing BNT116 in combination with checkpoint inhibitor drugs.¹⁴

Safety Profile Across Vaccine Types

One consistent finding across different lung cancer vaccines is that they tend to be well tolerated compared to chemotherapy or even many targeted drugs. CIMAvax-EGF’s most common side effects in real-world use were injection-site pain (about 24% of patients), fever (around 10%), and headache (about 9%). Serious adverse events were rare, occurring in three patients, and no deaths were attributed to the vaccine.¹⁵ The L-BLP25 vaccine showed a similar pattern: side effects in about two-thirds of patients were nearly all mild, with injection-site bruising, fatigue, and flu-like symptoms being the most common complaints.¹⁶ A universal cancer peptide vaccine tested in a phase I/IIa trial also found no dose-limiting toxicity among 15 patients.¹⁷

The mild side-effect profile matters for quality of life. In a randomized trial of the TG4010 vaccine added to standard chemotherapy, patients who received the vaccine had a similar evolution in health-related quality of life compared to those receiving chemotherapy alone, meaning the vaccine did not add a meaningful burden of symptoms on top of chemo.¹⁸

Pairing Vaccines with Checkpoint Inhibitors

Most researchers now believe that lung cancer vaccines will work best not as standalone treatments but in combination with drugs that remove the brakes from the immune system. Checkpoint inhibitors like pembrolizumab and cemiplimab block proteins that tumors use to shut down T cells. A vaccine can prime the immune system to recognize the cancer, and a checkpoint inhibitor can keep that response from being silenced.

Preclinical work supports this logic. In mice with established lung tumors, combining an anti-PD-1 checkpoint inhibitor with a dendritic cell vaccine loaded with tumor material led to 80% tumor eradication. The combination increased levels of key tumor-killing molecules in the tumor environment and ramped up the activity of T cells that had infiltrated the tumors.¹⁹ This synergy between vaccines and checkpoint inhibitors is now the dominant strategy being tested in clinical trials for lung cancer.

Why Lung Tumors Are Hard Targets

If vaccines can generate anti-tumor immune responses and checkpoint inhibitors can unleash them, why hasn’t this already solved lung cancer? The answer lies in the tumor’s own countermeasures. Lung cancers are remarkably good at evading the immune system, and they get better at it over time.

Even in pre-invasive lesions, before a tumor has fully formed, researchers have documented impaired antigen presentation, silencing of neoantigens, activation of immune checkpoints, and shifts in the balance of pro- and anti-inflammatory signaling. These escape mechanisms continue to evolve as the cancer becomes invasive, and they vary not just between patients but between different regions within the same tumor.²⁰ This intra-tumor heterogeneity is a major headache for vaccine design: a vaccine targeting neoantigens from one biopsy site might miss targets that dominate in another part of the same tumor.

One recently characterized escape mechanism involves a protein called TAP2 that helps display tumor proteins on the cell surface for immune recognition. Researchers found that lung cancer cells can silence TAP2, reducing the number of target molecules visible to T cells. This silencing is driven by IL-4, an immune signaling molecule, which alters the accessibility of the TAP2 gene. Crucially, this process was reversible, suggesting it could potentially be counteracted with the right drug combination.²¹

The Manufacturing Bottleneck for Personalized Vaccines

Personalized neoantigen vaccines sound ideal on paper, but making one is a logistical challenge. The current workflow involves surgically removing or biopsying tumor tissue, sequencing the DNA, predicting which neoantigens will work, manufacturing the vaccine, and running quality-control tests. That entire pipeline takes roughly four to seven weeks from surgery to the first dose.²² For a patient with aggressive, advanced lung cancer, several weeks of waiting is not trivial. The disease can progress during manufacturing, and the neoantigens identified from the original biopsy may no longer represent the dominant tumor population by the time the vaccine is ready.

Artificial intelligence is being applied to compress this timeline. Deep learning pipelines can analyze multi-omics datasets to predict tumor-specific mutations and rank candidate neoantigens for vaccine inclusion, reportedly improving both the speed and accuracy of neoantigen identification compared to older computational methods.²³ Still, even with AI assistance, the manufacturing and quality-control steps for mRNA or peptide vaccines require a minimum turnaround time that is hard to eliminate entirely.

Small Cell Lung Cancer Has Been a Tougher Case

Most lung cancer vaccine research focuses on non-small cell lung cancer, and for good reason. Small cell lung cancer, which makes up about 15% of cases, has proven far more resistant to vaccine approaches. A large phase III trial of the Bec2/BCG vaccine in over 500 patients with limited-stage small cell lung cancer found no improvement in survival, progression-free survival, or quality of life. Median survival was actually slightly shorter in the vaccinated group, though the difference was not statistically significant.²⁴

A more recent phase II trial used dendritic cells loaded with a tumor-suppressor gene (TP53) in patients with extensive-stage small cell lung cancer. The vaccine was safe, but immune responses were modest: about 20% of patients in the vaccine-only arm showed a positive response, rising to about 43% when the vaccine was combined with all-trans-retinoic acid. The vaccine did not improve response rates to subsequent chemotherapy.²⁵ Small cell tumors tend to be more genetically homogeneous in some ways but wildly aggressive, and they create a particularly hostile immune microenvironment. Whether newer mRNA or neoantigen approaches can crack this remains an open question.

Cost and Access

Even if lung cancer vaccines prove effective in larger trials, getting them to patients will involve navigating steep costs. Personalized vaccines, by definition, are one-off manufacturing runs for a single patient. Cost-effectiveness analyses of adjuvant immunotherapies in lung cancer show a wide range: some targeted approaches in specific biomarker-defined populations come in at favorable cost-per-quality-adjusted-life-year figures, while broad, unselected use of PD-1/PD-L1-based regimens can push costs above $300,000 to $600,000 per quality-adjusted life year gained.²⁶

Reimbursement decisions add another layer of uncertainty. An analysis of lung cancer drug coverage in Spain found that demonstrating substantial clinical benefit increased the probability of a positive reimbursement decision by 35 to 40 percentage points, but cost-effectiveness on its own did not significantly influence the outcome.²⁷ In other words, regulators want to see that a treatment actually helps patients before price negotiations even begin. For vaccines still in early-phase trials, generating the kind of survival data that drives reimbursement decisions is years away.

Patient willingness to pay for mRNA-based cancer treatments has been surveyed, and unsurprisingly, people value these therapies highly in the abstract. But what matters for access is whether health systems will cover them. Currently, patient and societal preferences carry limited weight in most countries’ coverage decisions compared to clinical evidence and budget impact.²⁸ Off-the-shelf vaccines like BNT116, which use fixed antigens and standardized manufacturing, may have an easier path to affordability than fully personalized neoantigen vaccines, simply because economies of scale apply.